Vasculitis

FDA to Review Avacopan for ANCA-Associated Vasculitis

Publish Date September 23, 2020

Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.

Specimen Length, Number of Sections Linked to Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis

Publish Date August 25, 2020

Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.

Iloprost May Be Useful in the Treatment of COVID-19 Vasculopathy

Publish Date July 27, 2020

Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.

Avacopan NDA Submitted for ANCA-Associated Vasculitis

Publish Date July 16, 2020

ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Long-Term Rituximab Linked to Reduced Incidence of ANCA-Associated Vasculitis

Publish Date June 12, 2020

Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.

Avacopan May Be Safe, Efficacious, and Superior to Other Treatments in ANCA-Associated Vasculitis

Publish Date June 5, 2020

Researchers evaluated the efficacy and safety of avacopan for the treatment of ANCA-associated vasculitis.

The Autoimmune COVID-19 Project: A Patient-Centered Initiative

Publish Date May 29, 2020

Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.

Ocular Complications Common Across Spectrum of Rheumatic Diseases

Publish Date May 19, 2020

Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.

Omalizumab Demonstrates Effectiveness in Normocomplementemic Urticarial Vasculitis

Publish Date May 8, 2020

Investigators characterized the effects and markers of response of omalizumab in normocomplementemic urticarial vasculitis.

PEXIVAS Trial Challenges the Benefits of Plasma Exchange, Glucocorticoid Use in ANCA-Associated Vasculitis

Publish Date April 22, 2020

Researchers in the PEXIVAS trial evaluated and challenged the effect of plasma exchange and glucocorticoid use in ANCA-associated vasculitis.